Blurbs

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Baxter International (BAX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mirum Pharmaceuticals (MIRMResearch Report) and Baxter International (BAXResearch Report) with bullish sentiments.

Mirum Pharmaceuticals (MIRM)

In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Mirum Pharmaceuticals, with a price target of $32.00. The company’s shares closed last Friday at $25.58.

According to TipRanks.com, Fye is a 4-star analyst with an average return of 7.1% and a 48.3% success rate. Fye covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Intra-Cellular Therapies, and Lexicon Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mirum Pharmaceuticals with a $53.83 average price target, representing an 117.6% upside. In a report issued on May 5, Robert W. Baird also maintained a Buy rating on the stock with a $35.00 price target.

See today’s best-performing stocks on TipRanks >>

Baxter International (BAX)

In a report released yesterday, Robbie Marcus from J.P. Morgan maintained a Buy rating on Baxter International, with a price target of $90.00. The company’s shares closed last Friday at $73.23.

According to TipRanks.com, Marcus is a 4-star analyst with an average return of 7.7% and a 45.9% success rate. Marcus covers the Healthcare sector, focusing on stocks such as Treace Medical Concepts, Integra Lifesciences, and Silk Road Medical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Baxter International with a $90.40 average price target, implying a 23.6% upside from current levels. In a report issued on May 17, Citigroup also maintained a Buy rating on the stock with a $85.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MIRM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos